Alnylam Pharmaceuticals | ALNY - Market Capitalization

Stock Price
335.55
Daily Change
-16.41 -4.66%
Monthly
-17.43%
Yearly
20.59%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $45B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
Agios Pharmaceuticals USD 2.33B 402M Sep/2025
Alnylam Pharmaceuticals USD 59.77B 17.25B Sep/2025
Amgen USD 184.41B 32.48B Feb/2026
Arrowhead Research USD 8.47B 3.7B Feb/2026
BioMarin Pharmaceutical USD 10.4B 142M Sep/2025
Incyte USD 16.56B 3.38B Sep/2025
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
Moderna USD 10.09B 581M Sep/2025
Neurocrine Biosciences USD 13.92B 1.48B Sep/2025
Novartis USD 303.91B 57.84B Feb/2026
PTC Therapeutics USD 4.88B 1B Sep/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sanofi EUR 118.94B 1.6B Feb/2026
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Takeda JPY 7.64T 774.9B Dec/2025
Tectonic Therapeutic USD 294M 77M Sep/2025
Ultragenyx Pharmaceutical USD 2.9B 539M Sep/2025
Vertex Pharmaceuticals USD 100.41B 13.91B Sep/2025
Xencor USD 837M 278M Sep/2025